Coronavirus Disease 2019: Coronaviruses and Blood Safety

Abstract With the outbreak of unknown pneumonia in Wuhan, China, in December 2019, a new coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), aroused the attention of the entire world. The current outbreak of infections with SARS-CoV-2 is termed Coronavirus Disease 2019 (COVID-19). The World Health Organization declared COVID-19 in China as a Public Health Emergency of International Concern. Two other coronavirus infections—SARS in 2002-2003 and Middle East Respiratory Syndrome (MERS) in 2012—both caused severe respiratory syndrome in humans. All 3 of these emerging infectious diseases leading to a global spread are caused by β-coronaviruses. Although coronaviruses usually infect the upper or lower respiratory tract, viral shedding in plasma or serum is common. Therefore, there is still a theoretical risk of transmission of coronaviruses through the transfusion of labile blood products. Because more and more asymptomatic infections are being found among COVID-19 cases, considerations of blood safety and coronaviruses have arisen especially in endemic areas. In this review, we detail current evidence and understanding of the transmission of SARS-CoV, MERS–CoV, and SARS-CoV-2 through blood products as of February 10, 2020, and also discuss pathogen inactivation methods on coronaviruses.

[1]  W. Handke,et al.  Inactivation of three emerging viruses – severe acute respiratory syndrome coronavirus, Crimean–Congo haemorrhagic fever virus and Nipah virus – in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light , 2020, Vox sanguinis.

[2]  H. Doerr,et al.  SARS-coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin preparation , 2005, Biologicals.

[3]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[4]  Xin Li,et al.  The clinical pathology of severe acute respiratory syndrome (SARS): a report from China , 2003, The Journal of pathology.

[5]  Christian Drosten,et al.  Identification of a novel coronavirus in patients with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[6]  L. Poon,et al.  Serial Analysis of the Plasma Concentration of SARS Coronavirus RNA in Pediatric Patients with Severe Acute Respiratory Syndrome , 2003, Clinical chemistry.

[7]  Jing Zhang,et al.  Detection and Monitoring of SARS Coronavirus in the Plasma and Peripheral Blood Lymphocytes of Patients with Severe Acute Respiratory Syndrome , 2004, Clinical chemistry.

[8]  Qianyun Liu,et al.  Emerging coronaviruses: Genome structure, replication, and pathogenesis , 2020, Journal of medical virology.

[9]  J. Reina,et al.  [The Middle East respiratory syndrome coronavirus]. , 2015, Medicina clinica.

[10]  P. Rebulla.  The long and winding road to pathogen reduction of platelets, red blood cells and whole blood , 2019, British journal of haematology.

[11]  R. Wunderink,et al.  MERS, SARS and other coronaviruses as causes of pneumonia , 2017, Respirology.

[12]  R. Bowen,et al.  Inactivation of Middle East respiratory syndrome coronavirus (MERS‐CoV) in plasma products using a riboflavin‐based and ultraviolet light‐based photochemical treatment , 2016, Transfusion.

[13]  Y. Lau,et al.  Chemokine up-regulation in SARS-coronavirus–infected, monocyte-derived human dendritic cells , 2005, Blood.

[14]  Q. Pham,et al.  Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam , 2020, The New England journal of medicine.

[15]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[16]  A. Osterhaus,et al.  Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. , 2012, The New England journal of medicine.

[17]  J. Sung,et al.  Quantitative Analysis and Prognostic Implication of SARS Coronavirus RNA in the Plasma and Serum of Patients with Severe Acute Respiratory Syndrome , 2003 .

[18]  Lanjuan Li,et al.  SARS-coronavirus replicates in mononuclear cells of peripheral blood (PBMCs) from SARS patients , 2003, Journal of Clinical Virology.

[19]  Yihua Zhou.  Prevalence of non-pneumonic infections with SARS-correlated virus , 2004, The Lancet.

[20]  B. Fielding,et al.  MERS-CoV: Understanding the Latest Human Coronavirus Threat , 2018, Viruses.

[21]  B. Biggerstaff,et al.  Theoretically estimated risk of severe acute respiratory syndrome transmission through blood transfusion during an epidemic in Shenzhen, Guangdong, China in 2003 , 2007, Transfusion and Apheresis Science.

[22]  C. Batéjat,et al.  Heat inactivation of the Middle East respiratory syndrome coronavirus , 2014, Influenza and other respiratory viruses.

[23]  H. Shan,et al.  Viral attacks on the blood supply: the impact of severe acute respiratory syndrome in Beijing , 2004, Transfusion.

[24]  A. Seltsam,et al.  Update on the use of pathogen‐reduced human plasma and platelet concentrates , 2013, British journal of haematology.

[25]  Yi Guan,et al.  Relative rates of non-pneumonic SARS coronavirus infection and SARS coronavirus pneumonia , 2004, The Lancet.

[26]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[27]  G. Damanhouri,et al.  Amotosalen and ultraviolet A light efficiently inactivate MERS‐coronavirus in human platelet concentrates , 2019, Transfusion medicine.

[28]  S. Lindstrom,et al.  First Case of 2019 Novel Coronavirus in the United States , 2020, The New England journal of medicine.

[29]  P. Talbot,et al.  Effect of pH and temperature on the infectivity of human coronavirus 229E. , 1989, Canadian journal of microbiology.

[30]  J. Sung,et al.  Detection of SARS coronavirus in plasma by real-time RT-PCR. , 2003, The New England journal of medicine.

[31]  Deborah R. Taylor,et al.  Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products , 2006, Transfusion.

[32]  W. Lim,et al.  Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome , 2004, The Lancet.

[33]  D. Falzarano,et al.  SARS and MERS: recent insights into emerging coronaviruses , 2016, Nature Reviews Microbiology.

[34]  E. Seifried,et al.  NAT screening of blood donors for severe acute respiratory syndrome coronavirus can potentially prevent transfusion associated transmissions , 2004, Transfusion.

[35]  K. Ikuta,et al.  Heat sensitivity of a SARS‐associated coronavirus introduced into plasma products , 2004, Vox sanguinis.

[36]  S. Lo,et al.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.

[37]  M. Yilla,et al.  SARS-coronavirus replication in human peripheral monocytes/macrophages , 2004, Virus Research.

[38]  Z. Memish,et al.  Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  F. Zeng,et al.  Prevalence of non-pneumonic infections with SARS-correlated virus , 2004, The Lancet.

[40]  Terence C W Poon,et al.  Serial Analysis of Plasma Proteomic Signatures in Pediatric Patients with Severe Acute Respiratory Syndrome and Correlation with Viral Load , 2004, Clinical chemistry.

[41]  H. Doerr,et al.  Stability and inactivation of SARS coronavirus , 2004, Medical Microbiology and Immunology.

[42]  I. Sola,et al.  Molecular Basis of Coronavirus Virulence and Vaccine Development , 2016, Advances in Virus Research.

[43]  P. Vollmar,et al.  Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany , 2020, The New England journal of medicine.

[44]  P. Woo,et al.  Viral Loads in Clinical Specimens and SARS Manifestations , 2004, Emerging infectious diseases.

[45]  A. Hassan,et al.  Inactivation of Middle East respiratory syndrome‐coronavirus in human plasma using amotosalen and ultraviolet A light , 2017, Transfusion.

[46]  Outbreak of acute respiratory syndrome associated with a novel coronavirus, China: third update , 2020 .

[47]  L. Corash,et al.  Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long‐wavelength ultraviolet light , 2005, Transfusion.

[48]  D. Hui,et al.  Severe acute respiratory syndrome and Toronto , 2003, Journal of epidemiology and community health.